QR Code

Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer

Abstract Background Epidermal growth factor receptor (EGFR) mutations represent one of the most frequent oncogenic driver in non-small cell lung cancer (NSCLC). Amivantamab, a bispecific antibody targeting EGFR and MET proto-oncogene, receptor tyrosine kinase (MET), has demonstrated clinical benefit...

Full description

Saved in:
Main Authors: Ryo Yoshichika, Fumiaki Mukohara, Kotaro Yamada, Joji Nagasaki, Hiroko Watanabe, Youki Ueda, Ken Suzawa, Kazuhiko Shien, Shinichi Toyooka, Takamasa Ishino, Yosuke Togashi
Format: Artigo
Language:Inglês
Published: Springer 2026-03-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Non-small cell lung cancer
Amivantamab
Antitumor immunity
EGFR
MET
Online Access:https://doi.org/10.1007/s00262-026-04369-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items